Dose: 0.1 ml/kg
Single Dose: 0.1 (0.1)
Frequency: As recommended.
Route: IV
Instructions: For less than 60 kg. If the arrhythmia does not terminate within 10 min after the end of the initial infusion, a second 10 min infusion of equal strength may be administered 10 min after completion of the first

. It is of Synthetic origin and belongs to Methanesulfonamide. . The Molecular Weight of Ibutilide (Fumarate) is 884.00. Its pKa is 8.4, 9.6.

Ibutilide (Fumarate) is contraindicated in conditions like Hypersensitivity,Pregnancy,Ventricular tachyarrhythmias,Torsade de pointes.

The severe or irreversible adverse effects of Ibutilide (Fumarate), which give rise to further complications include Sinus tachycardia, Hypertension, Torsades de pointes, QT prolongation.Ibutilide (Fumarate) produces potentially life-threatening effects which include Polymorphic ventricular tachycardia. which are responsible for the discontinuation of Ibutilide (Fumarate) therapy.The signs and symptoms that are produced after the acute overdosage of Ibutilide (Fumarate) include Ventricular ectopy.The symptomatic adverse reactions produced by Ibutilide (Fumarate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Diarrhea, Hypotension, Renal failure, AV Block, Sinus bradycardia, Supraventricular tachycardia, Nodal arrhythmias, Congestive heart failure, Idioventricular rhythm, dizziness.

Ibutilide (Fumarate) is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Ventricular tachycardia.

Ibutilide (Fumarate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementVORICONAZOLEAdditive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

None well documented

Drug should not be given to Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store Between 20°C-25°C. Protect from Sunlight.

The ECG should be monitored continuously during infusion and for at least 4 hours after administration. The infusion should be stopped as soon as the arrhythmia is terminated.